Serum Estradiol Levels with Femring
Femring produces average serum estradiol concentrations of approximately 40.6 pg/mL with the 0.05 mg/day dose and 76 pg/mL with the 0.10 mg/day dose, with peak levels (Cmax) reaching 1129 pg/mL and 1665 pg/mL respectively within the first hour after insertion. 1
Pharmacokinetic Profile
The estradiol levels with Femring follow a distinct pattern:
Initial Peak Phase (0-48 hours)
- Cmax occurs rapidly at approximately 0.7-0.9 hours (mean Tmax) after ring insertion
- 0.05 mg/day ring: Peak of 1129 pg/mL (±25% RSD)
- 0.10 mg/day ring: Peak of 1665 pg/mL (±23% RSD)
- After this initial spike, concentrations decline over the first 24-48 hours 1
Steady-State Phase (After 48 hours through 3 months)
- 0.05 mg/day ring: Average steady-state of 40.6 pg/mL (±26% RSD)
- 0.10 mg/day ring: Average steady-state of 76 pg/mL (±24% RSD)
- These levels remain relatively constant for the remainder of the 3-month dosing interval 1
Clinical Context
Important caveat: Femring is a systemic estrogen delivery system, not a low-dose vaginal estrogen product. The FDA label clearly indicates it delivers systemic estradiol levels and requires concomitant progestogen in women with a uterus to prevent endometrial hyperplasia 2. This distinguishes it from low-dose vaginal rings (like Estring) that maintain estradiol within the postmenopausal range.
Comparison to Other Formulations
- The steady-state levels achieved by Femring fall within the postmenopausal to early follicular phase range of premenopausal women 3
- These levels are lower than typical oral estradiol preparations but provide consistent systemic exposure 2
- The vaginal route avoids first-pass hepatic metabolism, resulting in estradiol levels that are slightly higher than estrone levels (unlike oral administration) 1
Estrone and Estrone Sulfate Levels
Accompanying estradiol levels, Femring also produces:
- 0.05 mg/day: Estrone 35.9 pg/mL, Estrone sulfate 494.6 pg/mL
- 0.10 mg/day: Estrone 45.7 pg/mL 1
Practical Considerations
Monitoring is generally not required for routine symptom management with Femring, as guidelines recommend titrating to clinical response rather than specific estradiol levels 2. However, measurement may be useful if symptoms don't improve with dose escalation or when changing between administration routes.
The initial high peak followed by steady lower levels is a characteristic feature of this delivery system, with in vitro studies showing this initial release increases as rings age during storage 1.